LabSat, for research applications, has been released for commercialization. The news was announced by Lunaphore Technologies SA, a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics.
LabSat, a CE-marked instrument is in compliance with all applicable product health, safety and environmental regulations of the European Union and will be available in most European countries.
LabSat is the first solution in Lunaphore’s pipeline to reach the market since the foundation of the company. The system consists of a single-slide, automated reagent delivery system performing immunohistochemistry (IHC) tests on tissue samples within 10 to 30 minutes. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.
Lunaphore’s Founder and CEO, Ata Tuna Ciftlik, said: “This very first product aims to bring our breakthrough technology to the hands of our customers. We believe that its precision and speed will open a multitude of staining possibilities for the users,” and added: “In parallel, we’re working on the next product iterations to answer the needs of customers with greater needs of automation as well as a wider portfolio of applications.”
At the moment, the company is developing as well a solution for the In-Vitro Diagnostics field, which aims to launch in the near future.
Note: IHC staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. IHC is the most frequently performed biomarker test in routine cancer diagnostics* following a biopsy procedure, as well as common test in immuno-oncology research. During an IHC test, the tissue sample is stained with labelled antibodies – producing a tissue coloring visible with a microscope- that will signal the presence and localization of specific cancer biomarkers, in order to support clinicians and researchers in the identification of specific cancer types.